- Correspondence
- Open access
- Published:
Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting
Journal of Hematology & Oncology volume 17, Article number: 84 (2024)
Abstract
Combination of immunotherapy with radiotherapy is under active investigation. The PACIFIC trial firmly established the treatment paradigm of consolidation immunotherapy following definitive chemoradiotherapy, inspiring a series of similar or exploratory combination regimens. This summary highlighted six reports updated in the 2024 ASCO Annual Meeting.
Consolidation immunotherapy following concurrent chemoradiotherapy
Consolidation immunotherapy following definitive concurrent chemoradiotherapy (cCRT) has been established as a standard treatment in unresectable locally advanced non-small cell lung cancer (LA-NSCLC) based on the PACIFIC trial [1]. This strategy was further validated in a real-world study with superior survival outcomes at ASCO 2024 [2]. Moreover, research has been conducted to investigate the efficacy of consolidation immunotherapy in limited-stage small-cell lung cancer (LS-SCLC). The phase III ADRIATIC study evaluated durvalumab as a consolidation treatment for LS-SCLC patients who had not experienced disease progression after cCRT (Table 1). Results from the study showed that durvalumab consolidation significantly prolonged overall survival [median OS (mOS): 55.9 vs. 33.4 months; HR 0.73; p = 0.0104] and progression-free survival [median PFS (mPFS): 16.6 vs. 9.2 months; HR 0.76; p = 0.0161] compared to placebo (Table 2). The incidence rates of grade 3/4 adverse events (AEs) were similar at 24%, with less than 3% experiencing grade 3/4 pneumonitis across both groups [3]. The ADRIATIC study would be a game-changer, and durvalumab would be a new standard of care for LS-SCLC after concurrent chemoradiotherapy.
While consolidation immunotherapy is the standard treatment for LA-NSCLC patients, its application in patients with a driver gene mutation is still largely unknown. A global retrospective study revealed consolidation with ALK tyrosine kinase inhibitors (ALK-TKI) significantly improved PFS in ALK-positive unresectable LA-NSCLC compared to durvalumab or observation after cCRT ([not reached [NR]] vs. 11.3 months vs. 7.4 months, p < 0.0001) (Table 2) [4]. Meanwhile, the LAURA study in this year’s ASCO meeting demonstrated that consolidation therapy with osimertinib following cCRT in EGFR-mutant locally advanced patients achieved a significantly prolonged median PFS of 39.1 months [5]. In contrast, in the PACIFIC trial, the median PFS of patients with EGFR mutations was 11.2 months. The ongoing BO42777 trial aims to evaluate the safety and efficacy of multiple targeted therapies compared to durvalumab for patients with unresectable stage III NSCLC [6]. The anticipated results will provide valuable insights into the efficacy of consolidation targeted therapies.
Neoadjuvant immunotherapy plus chemotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy
Researchers have been exploring immunotherapy as a component of a neoadjuvant strategy to improve survival outcomes in locally advanced tumors. Dr. Mai et al. reported the interim findings from the phase III BEACON study, which compared the efficacy of induction tislelizumab versus placebo combined with chemotherapy (gemcitabine-cisplatin), followed by cCRT and adjuvant tislelizumab or placebo in patients with locoregionally advanced nasopharyngeal carcinoma. The tislelizumab arm demonstrated a significant increase in the complete response rate (CRR) compared to the placebo arm (30.5% vs. 16.7%; p = 0.0006), meeting the primary endpoint (Table 2) [7]. It is expected that the significant tumor shrinkage effect would be converted into survival benefits.
The GASTO-1091 study enrolled unresectable LA-NSCLC patients who received neoadjuvant docetaxel, cisplatin, and nivolumab followed by hypofractionated cCRT (hypo-cCRT). The hypo-cCRT was administered with a dose of 40 Gy in 10 fractions (fx) or 30 Gy in 6fx, followed by a hypo-cCRT boost of 24-30 Gy in 6fx, resulting in a total dose of 60-64 Gy. Patients without progression or grade ≥ 2 pneumonitis after hypo-cCRT were subsequently randomized to receive nivolumab or undergo observation. The study’s primary endpoint was met, with the nivolumab group demonstrating significantly extended PFS compared to the observation group (NR vs. 12.2 months, p = 0.002) [8]. Notably, the control group in this study had a PFS of 12.2 months, which is substantially longer than the 5.6 months observed in the PACIFIC study’s control group. Additionally, both groups exhibited high overall response rates (ORR) with a minor difference (98.8% vs. 97.7%). These findings support further investigation of this innovative modality.
Neoadjuvant immunotherapy plus radiotherapy followed by surgery and adjuvant immunotherapy
A phase II study (SU2C-SARC032) demonstrated a significant enhancement in disease-free survival (DFS) when utilizing neoadjuvant pembrolizumab and radiotherapy (50 Gy/25fx), followed by surgery and adjuvant pembrolizumab (EXP), compared to standard radiotherapy and surgery (SOC) in undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS) (HR 0.57, 90%CI: 0.35-0.91; p = 0.023) (Table 2). The estimated 2-year DFS rate was higher in the EXP arm (70% vs. 53%) [9]. The superior DFS found in this study would potentially revolutionize the treatment paradigm for these specific cancer types in the future.
However, in terms of the AEs, the incidence of grade ≥ 3 was significantly higher in the EXP arm compared to the SOC arm in this study (52% vs. 26%, p = 0.002) (Table 2). Meanwhile, the PACIFIC-2 study evaluated the efficacy and safety of durvalumab in combination with cCRT, followed by consolidation durvalumab, as compared to placebo in patients with LA-NSCLC. The study did not demonstrate a statistically significant improvement in PFS (mPFS: 13.8 vs. 9.4 months, HR 0.85; 95% CI: 0.65-1.12; p = 0.247) or OS (mOS: 36.4 vs. 29.5 months, HR 1.03; 95% CI: 0.78-1.39; p = 0.823). Moreover, a notably higher percentage of patients experienced adverse events leading to the discontinuation of durvalumab compared to those receiving placebo (25.6% vs. 12.0%) [10], underscoring the importance of vigilant monitoring for potential adverse effects when concurrent combining immunotherapy with radiotherapy.
Sequential radiotherapy after first-line immunotherapy plus chemotherapy for advanced cancer
Local radiotherapy has shown promise in managing metastatic malignancies. Chen et al. reported on the efficacy and safety of sequential thoracic radiotherapy following immunotherapy plus EP/EC (etoposide and cisplatin or carboplatin) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). Among patients who responded to treatment, radiotherapy was administrated at a dose of ≥ 30 Gy/10fx or 50 Gy/25fx. The median OS and PFS were 21.4 months (95%CI: 17.2-NR) and 10.1 months (95%CI: 6.9-15.5), respectively, after a median follow-up of 17.7 months. The one-year and two-year OS rates were found to be 74.1% and 39.7%, respectively, while grade ≥ 3 treatment-related AEs occurred in 58.2% of patients (Tables 1 and 2) [11]. Furthermore, a randomized phase III study on thoracic radiotherapy for ES-SCLC is ongoing, and its results are eagerly anticipated [12].
In conclusion, these results highlighted the importance of combining radiotherapy and immunotherapy in solid tumors. Consolidation immunotherapy following cCRT has demonstrated survival benefits in both LA-NSCLC and LS-SCLC. Meanwhile, neoadjuvant immunotherapy combined with chemotherapy/radiotherapy has shown significant tumor shrinkage effects and might convert to survival outcomes. Additionally, incorporating radiotherapy into first-line treatment for advanced tumors has yielded promising results. However, concurrent immunotherapy and radiotherapy are currently being tested for extremity sarcoma and might not be recommended off-trial for chest tumors due to the negative results observed in the PACIFIC-2 trial. Further study is needed to elucidate the potential underlying mechanism for proper cooperation of radiotherapy and immunotherapy in the future.
Data availability
No datasets were generated or analysed during the current study.
Abbreviations
- cCRT:
-
Concurrent chemoradiotherapy
- LA-NSCLC:
-
Locally advanced non-small cell lung cancer
- LS-SCLC:
-
Limited-stage small-cell lung cancer
- OS:
-
Overall survival
- PFS:
-
Progression-free survival
- AEs:
-
Adverse events
- TKI:
-
Tyrosine kinase inhibitors
- NR:
-
Not reached
- CRR:
-
Complete response rate
- hypo-cCRT:
-
Hypofractionated concurrent radiotherapy and chemotherapy
- fx:
-
Fractions
- ORR:
-
Overall response rates
- DFS:
-
Disease-free survival
- EXP:
-
Neoadjuvant pembrolizumab and radiotherapy followed by surgery and adjuvant pembrolizumab
- SOC:
-
Standard radiation therapy and surgery
- UPS:
-
Undifferentiated pleomorphic sarcoma
- LPS:
-
Liposarcoma
- ES-SCLC:
-
Extensive-stage small-cell lung cancer
References
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. New Engl J Med. 2017;377(20):1919–29.
Mirsky MM, Lee HJ, Margevicius SP, Carsel A, Myers K, Zablonski K, Zhong J, Fu P, Wang Q, Dowlati A, Bruno DS, Hsu ML. Treatment outcomes in locally advanced, unresectable NSCLC treated with concurrent chemoradiation and PD-L1 consolidation: real-world data from a NCI comprehensive cancer center with a racially diverse, high poverty catchment area. J Clin Oncol. 2024;42(16suppl):8067–8067.
Spigel DR, Cheng Y, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A. ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). J Clin Oncol. 2024;42(17suppl):LBA5–5.
Jayakrishnan R, Nassar A, Shepherd FA, Lin JJ, Lin SH, Shakya P, Dilling TJ, Bar J, Grohe C, Gupta S, Fitzgerald BG, Adib E, Sankar K, Neal JW, Yu HA, Whitaker R, Velazquez Manana AI, Naqash AR, Goldberg SB, Kim SY. Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK + non-small cell lung cancer (NSCLC). J Clin Oncol. 2024;42(16suppl):8013–8013.
Ramalingam SS, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JCH, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Huang X, Gronde Tvd, Ghiorghiu DC, Lu S. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: primary results of the phase 3 LAURA study. J Clin Oncol. 2024;42(17suppl):LBA4–4.
Paz-Ares, Gay CM, Zhou C, Kato T, Corrales L, Redhead K, Rahman A, Bradley D, Theogaraj E, Hutchinson KE, Shagan SM, Solomon BJ. A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC). J Clin Oncol. 2024;42(17suppl):TPS8605–8605.
Mai HQ, Liu SL, Chen QY, Tang LQ, Jin F, Guo L, Luo H, Hu Y, Liu H, Liang JH. Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial. J Clin Oncol. 2024;42(16suppl):6001–6001.
Liu H, Qiu B, Zhao Y, He W-z, Feng W, Zeng W, Jia J, Meng F, Wang D, Liu F. A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091). J Clin Oncol. 2024;42(16suppl):8008–8008.
Mowery YM, Ballman KV, Hong AM, Schuetze S, Wagner AJ, Monga V, Heise R, Attia S, Choy E, Burgess MA, et al. SU2C-SARC032: a randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma. J Clin Oncol. 2024;42(16suppl):11504–11504.
Bradley J, Sugawara S, Lee K, Ostoros G, Demirkazik A, Zemanova M, Sriuranpong V, Gelatti A, Menezes J, Zurawski B. LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2. ESMO Open. 2024;9(3suppl):102986.
Chen D, Gao A, Zou B, Huang W, Shao Q, Meng X, Zhang P, Tang X, Hu X, Zhang Y, Guo J, Zhao W, Fu L, Zhao C, Yuan J, Yu J, Wang L. Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer. J Clin Oncol. 2024;42(16suppl):8014–8014.
Nosaki K, Zenke Y, Nomura S, Sasaki T, Niho S, Yoh K, Yoshioka H, Hosomi Y, Okamoto I, Kaneda H, Akamatsu H, Okamoto H, Sasaki K, Sekino Y, Horinouchi H, Ohe Y. JCOG2002: a randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer. J Clin Oncol. 2024;42(16suppl):TPS8132–8132.
Acknowledgements
This is not applicable for this summary.
Funding
The study is supported by the Science and Technology Commission of Shanghai Municipality (No. 23Y11908700) and the Clinical Research Key Project of Shanghai Pulmonary Hospital (FKLY20006).
Author information
Authors and Affiliations
Contributions
Yaping Xu and Shengxiang Ren designed the study. Yaping Xu, Di Liu, and Leilei Wu drafted the manuscript. Di Liu and Leilei Wu prepared the tables. Di Liu, Leilei Wu, Xiaoling Xu, Shuangyan Yang, Ming Liu, and Min Hu participated in the drafting process. Yaping Xu and Shengxiang Ren revised the manuscript.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
This is not applicable for this summary.
Consent for publication
This is not applicable for this summary.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Liu, D., Wu, L., Xu, X. et al. Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting. J Hematol Oncol 17, 84 (2024). https://doi.org/10.1186/s13045-024-01587-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13045-024-01587-w